INSIGHTS ON CELL & GENE CLINICAL TRIALS

• The Evolving Landscape Of Radiopharmaceuticals In Oncology Research

  From selecting appropriate targeting molecules to optimizing dosing strategies and managing off-target effects, radiopharmaceutical development demands a tailored and strategic clinical approach.

• Navigating CGT Biotech's Financial Headwinds And The Path Forward

  Dr. Ali Pashazadeh, Founder of Treehill Partners shares how CGT companies can navigate today’s biotech downturn by embracing integrated strategies, disciplined capital use, and bold leadership willing to rethink traditional models across innovation, manufacturing, and commercialization.

• Oncology Clinical Trials Case Study: I-SPY 2 & OpenClinica

  The I-SPY 2 trial represents a pioneering effort in the field of oncology, specifically targeting the development of personalized treatments for breast cancer.

• Consent By Proxy: The Key To More Inclusive, More Reliable Trials

  Explore innovative digital workflow designed specifically for Legally Authorized Representative (LAR) to help overcome the challenges of complex documentation and data management issues.

• EHR-To-EDC Success In A Complex, Adaptive Platform Trial

  I-SPY 2, one of the longest-running adaptive platform trials in oncology, is revolutionizing breast cancer research through a dynamic, data-driven approach to evaluating novel therapies.

• Unlocking Recruitment Potential In Trial-Naïve Sites

  Site Professional Support enabled this late-phase rheumatoid arthritis study to conduct complex patient visits despite it's use of sites that lacked research experience and resources.

• Delivering Specialist Neurology Support

  Explore a strategic approach to a Parkinson’s disease trial that leveraged a global infrastructure and multilingual workforce to provide seamless operational and clinical support.

• Enhance Access And Improve Retention In Rare Disease Trials With HTS

  Home Trial Support (HTS) provides a solution to improving participant recruitment and retention during musculoskeletal studies.

• High Density, Low Availability: Rethinking Ophthalmic Trial Readiness

  The adoption of mobile ophthalmic solutions and collaboration with specialized vendors is recommended to ensure trial consistency and reach underserved regions.

• Accelerate Your Oncology Breakthroughs

  Finding the right partnership can help your oncology clinical trials overcome trial complexities through strategic planning, a deep scientific understanding, and operational excellence.